The Platform
Extracellular Vesicle
Technology.
The Next Frontier.
What Are EVs?
The Communication
System of Regeneration.
Extracellular Vesicles (EVs) are nano-sized biological particles — ranging from 30 to 1,000 nanometres in diameter — that are secreted by virtually every cell type in the human body. They carry a complex cargo of proteins, lipids, messenger RNA, and microRNA that regulates cell behaviour, tissue repair, and immune function.
When stem cells secrete EVs, those vesicles carry the regenerative instructions that drive tissue repair. BICC's platform harnesses this mechanism — isolating, purifying, and delivering therapeutic EVs at clinical scale.
This is not a supplement. This is not a cosmetic. This is a next-generation biologic — and BICC holds the intellectual property to commercialise it.
EV PLATFORM AT A GLANCE | - |
|---|---|
NASDAQ Status | Pathway — 2026 |
Manufacturing Grade | GMP-Compatible |
Cryostability | >90% activity post-thaw |
Isolation Purity | >95% (BICC Protocol) |
Source Cells | Mesenchymal Stem Cells (MSCs) |
Cargo Types | Proteins, Lipids, mRNA, miRNA |
Vesicle Size Range | 30–1,000 nm |
The Advantage
Why EVs.
Why Now.
The EV field is at the same inflection point that monoclonal antibodies occupied in the 1990s — a scientifically validated platform with enormous therapeutic potential, still in the early stages of commercial development. BICC is building the infrastructure to lead this transition.
No Live Cell Transfer
EVs deliver the regenerative signals of stem cells without the complexity, regulatory burden, or safety concerns of live cell transplantation. This dramatically simplifies the path to clinical application.
Immune-Privileged Delivery
Unlike whole-cell therapies, EVs are largely immune-invisible — they can be administered across HLA barriers without triggering rejection, enabling off-the-shelf therapeutic products.
Multi-Cargo Delivery
A single EV carries hundreds of bioactive molecules — proteins, lipids, mRNA, and miRNA — delivering a complex therapeutic payload that no synthetic drug can replicate.
Scalable Manufacturing
BICC's proprietary culture and isolation protocols enable GMP-grade EV production at commercial scale — a critical capability that most EV research programmes lack.
Intellectual Property
The Patent Portfolio.
The Moat.
BICC's five-patent portfolio spans the full value chain of EV therapy — from upstream cell culture to downstream formulation and delivery. This integrated IP position is the scientific moat that protects BICC's commercial advantage.
P01
Stem Cell Culture & Expansion System
GRANTED
Regenerative Medicine :
A proprietary method for culturing and expanding mesenchymal stem cells at clinical scale, maintaining phenotypic stability across multiple passages — the foundational platform for all downstream EV production.
P02
Exosome Biologic Isolation & Purification
GRANTED
EV Therapy :
A novel multi-step isolation protocol that achieves >95% purity of therapeutic EVs from conditioned media, eliminating cellular debris and non-vesicular contaminants that compromise therapeutic efficacy.
P03
Regenerative Wound Healing Formulation
GRANTED
Wound Care :
An EV-enriched topical formulation that accelerates wound closure by 40% vs. standard of care in preclinical models, with applications in diabetic wound management, burns, and post-surgical recovery.
P04
Cryopreservation Protocol for EV Biologics
FILED
Manufacturing :
A stabilisation and cryopreservation methodology that preserves >90% of EV biological activity after freeze-thaw cycles, enabling global distribution of EV therapeutics without cold-chain compromise.
P05
Immune Cell Activation & Modulation Platform
FILED
Immunotherapy :
A platform for EV-mediated immune cell modulation, enabling targeted activation or suppression of immune responses — with applications in autoimmune disease, cancer immunotherapy, and aging-related immune decline.
Clinical Pipeline
From Lab to Market.
A Defined Pathway.
INDICATION | STAGE | TIMELINE | PARTNER |
|---|---|---|---|
Neurodegenerative Disease | Discovery | Preclinical: 2028 | BICC Internal |
Age-Related Immune Decline | Research | IND Filing: 2027 | BICC Internal |
Metabolic Syndrome | Research | IND Filing: 2027 | Biotech & Biomedicine (Shenyang) |
Regenerative Wound Healing | Preclinical | Phase I: 2026 | Beijing Tianyi Yuanfang |
Longevity Nutraceuticals (TSG) | Commercial | Live — 2024 | The Stemcell Group |